Parkinson disease, L-dopa, and neuropathy Did we miss something?

被引：5
|
作者：
Tison, Francois [1 ,2 ,3 ]
Le Masson, Gwendal [2 ,4 ]
机构：
[1] CHU Bordeaux, Serv Neurol, GH Sud, Hop Haut Leveque, F-33604 Pessac, France
[2] Bordeaux Univ, Bordeaux, France
[3] CNRS, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France
[4] INSERM 862, Inst Francois Magendie, Bordeaux, France
来源：
NEUROLOGY | 2011年 / 77卷 / 22期
关键词：
HOMOCYSTEINE LEVELS; LEVODOPA;
D O I：
10.1212/WNL.0b013e31823de107
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1938 / 1939
页数：2
相关论文
共 50 条
  • [41] Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients
    Bartosova, O.
    Bonnet, C.
    Ulmanova, O.
    Sima, M.
    Perlik, F.
    Ruzicka, E.
    Slanar, O.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (04) : 699 - 703
  • [42] Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa
    A. W. Michell
    Z. Xu
    D. Fritz
    S. J. G. Lewis
    T. Foltynie
    C. H. Williams-Gray
    T. W. Robbins
    R. H. S. Carpenter
    R. A. Barker
    Experimental Brain Research, 2006, 174 : 7 - 18
  • [43] L-DOPA IN PARKINSONS DISEASE
    CLEGHORN, RA
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1970, 102 (13) : 1410 - &
  • [44] Arguments favoring early treatment of Parkinson's disease with L-Dopa
    Broussolle, E
    REVUE NEUROLOGIQUE, 1999, 155 (01) : 27 - 33
  • [45] Molecular mechanism of L-Dopa induced dyskinesia in Parkinson's disease
    Subhani, F. U. -H.
    Subhani, A.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S118 - S119
  • [46] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    MOVEMENT DISORDERS, 2011, 26 : S259 - S259
  • [47] L-dopa impairs learning, but spares generalization, in Parkinson's disease
    Shohamy, D
    Myers, CE
    Geghman, KD
    Sage, J
    Gluck, MA
    NEUROPSYCHOLOGIA, 2006, 44 (05) : 774 - 784
  • [48] Impact of l-dopa on sleep and cognitive performance in Parkinson's disease
    Holinka, B
    Ruff, H
    Malak, J
    Calabrese, P
    Gehlen, W
    SLEEP, 2002, 25 : A256 - A256
  • [49] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    SCOTTISH MEDICAL JOURNAL, 2012, 57 (04) : 217 - 220
  • [50] Saccadic latency distributions in Parkinson's disease and the effects of L-dopa
    Michell, A. W.
    Xu, Z.
    Lewis, S. J. G.
    Foltynie, T.
    Williams-Gray, C. H.
    Robbins, T. W.
    Carpenter, R. H. S.
    Barker, R. A.
    EXPERIMENTAL BRAIN RESEARCH, 2006, 174 (01) : 7 - 18
12345